Physician profile
David E Konigsberg
NPI 1114178142
$1,883.51
in general payments reported to CMS, 2019-2025
31 companies · $205 in 2025
The $205 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $199 · 2020: $262 · 2021: $315 · 2022: $245 · 2023: $427 · 2024: $230 · 2025: $205.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $862.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $862.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $378.65 | 2019-2024 | Rybelsus, Ozempic |
| Lilly USA, LLC | $175.53 | 2020-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $153.36 | 2019-2025 | Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $127.01 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $102.35 | 2019-2025 | Farxiga, Airsupra |
| Janssen Pharmaceuticals, INC | $95.74 | 2021 | |
| Pfizer INC. | $93.21 | 2021-2024 | |
| Exact Sciences Corporation | $72.79 | 2024-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $71.85 | 2020-2023 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $63.81 | 2019-2022 | |
| Dexcom, INC. | $47.70 | 2023 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $44.56 | 2022-2023 | |
| Genentech USA, INC. | $42.75 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.50 | 2020-2023 | Jardiance |
| Abbott Laboratories | $42.10 | 2023 | Proclaim, Freestyle Libre 3 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $41.16 | 2019-2023 | |
| Corcept Therapeutics | $36.02 | 2023 | Korlym |
| Amgen INC. | $29.45 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $29.16 | 2019-2025 | Zoryve |
| Radius Health, INC. | $21.99 | 2025 | |
| Medtronic, INC. | $20.86 | 2024 | Intellis Adaptivestim |
| Ascensia Diabetes Care US INC. | $18.39 | 2024 | |
| Cranial Technologies, INC | $18.09 | 2025 | Doc Band |
| Biogen, INC. | $16.85 | 2025 | Spinraza |
| Organogenesis INC. | $15.36 | 2025 | Affinity |
| Bausch Health US, LLC | $14.86 | 2021 | |
| Sanofi-Aventis U.S. LLC | $14.77 | 2020 | |
| Dynavax Technologies Corporation | $14.71 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $13.93 | 2021 | |
| Esperion Therapeutics, INC. | $12.68 | 2022 | |
| Amarin Pharma, INC. | $11.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Konigsberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.